Q-omics provides the consensus-scored ADH5P4 profile across patient tissues and cancer cell-line models. ADH5P4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ADH5P4 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, ADH5P4 RNA expression shows 14,998 significant gene co-expression associations, with the highest sampling consensus in KICH. Together, these results highlight KIRC, THCA, and KICH as cancer lineages where ADH5P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADH5P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADH5P4 survival associations across molecular data types. ADH5P4 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADH5P4 RNA expression–survival associations across cancer types. High ADH5P4 expression shows unfavorable associations in STAD, but favorable associations in KIRC, READ, THCA, COAD and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ADH5P4 RNA expression.
This table summarizes ADH5P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ADH5P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADH5P4 shows lower tumor expression in THCA, KICH, BRCA and KIRP and higher tumor expression in HNSC and COAD. The THCA box plot shows higher ADH5P4 RNA expression in normal versus tumor tissue (log2 FC = −0.222, t-test p < 0.001).
This table shows molecular features associated with ADH5P4 in patient tissues and cancer cell lines. In patient samples, ADH5P4 shows the broadest associations at the RNA and protein expression levels, with KICH recurring as the lineage with the largest associated feature set.
